Journal
EPILEPSY RESEARCH
Volume 104, Issue 1-2, Pages 140-150Publisher
ELSEVIER
DOI: 10.1016/j.eplepsyres.2012.08.005
Keywords
Levetiracetam; Monotherapy; Quality of life; Depression; Anxiety
Categories
Funding
- UCB
- Pfizer
- Eisai
- Novartis
- GSK
- Janssen-Cilag
- Desitin
- Sanofi Pasteur MSD
- Desitin Germany
- Eisai Canada
- Deutsche Forschungsgemeinschaft
- Glaxo-Smith-Kline
Ask authors/readers for more resources
The aim of this study was to investigate the change of health related quality of life (HRQoL), anxiety and depression in adult patients in whom an adjunctive treatment with levetiracetam (LEV) was converted to a LEV monotherapy. A prospective, open, investigator initiated multicenter study enrolled 140 patients in whom LEV was added to the existing antiepileptic medication. A total of 65 patients who benefited from the 16-week add-on treatment with LEV (>= 50% seizure reduction) were converted to LEV monotherapy (16-week follow-up). In LEV responders, HRQoL, anxiety and depression improved after add-on of LEV. The subsequent conversion to LEV monotherapy did not lead to a significant change in HRQoL, anxiety and depression. However, comparing baseline with LEV monotherapy, the improvements remained significant for most dimensions of HRQoL and for anxiety and depression. Patients' ratings of efficacy of LEV were related with their HRQoL after the conversion to monotherapy. Add-on therapy of LEV improved HRQoL, anxiety and depression in LEV responders. Conversion to a LEV monotherapy did not inevitably improve HRQoL in LEV responders, but the positive effect was maintained in the majority of the patients. The effects were highly related to seizure reduction. (c) 2012 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available